In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model. This strategic move is in line with ProPhase's evolution from a high complexity molecular Covid testing laboratory to an advanced WGS pioneer. The Company's state-of-the-art WGS lab, featuring four cutting-edge sequencing platforms, including two high-capacity, low cost, WGS machines, sets a precedent in
“ProPhase transformed itself from a supplement manufacturer to a leader in the Covid testing space,” said Ted Karkus, CEO of ProPhase Labs. “Jason was directly responsible for developing and managing all of the major business customers for Covid testing. His expertise in sales as well as his operational coordination with all the other departments in the lab was pivotal in scaling the Covid business.”
“He is already working on multiple opportunities aimed at absorbing a substantial portion of the company’s current sequencing capacity,” Mr. Karkus concluded.
“On the direct-to-consumer front, we are working towards launching a new, lower-cost product in 2024, one that we believe will significantly impact the consumer genetic testing market. To further bolster our efforts, we have recently engaged a top-tier marketing, growth, and branding agency, along with key business and marketing executives who will play pivotal roles in assisting us in the scale out of the business.”
“I am honored to lead Nebula and am eager to collaborate with our team to deliver substantial near and long term returns for our shareholders,” concluded
About
Forward Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our plans to grow our subsidiaries and build a multi-billion dollar company, our belief that our WGS lab is poised to revolutionize the genomics industry, our expected timeline for launching a new lower-cost direct-to-consumer WGS product, and our belief that such product will significantly impact the consumer genetic testing market. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other
For more information, visit www.ProPhaseLabs.com.
ProPhase Media Relations and Institutional Investor Contact:
267-880-1111
investorrelations@prophaselabs.com
ProPhase Retail Investor Relations Contact:
514-939-3989
Jboidman@renmarkfinancial.com
Source:
Source:
2024 GlobeNewswire, Inc., source